{"entity":{"id":"dt-7012","kind":"drug","name":"DT-7012","aka":[],"tldr":"DT-7012 is an experimental monoclonal antibody from Domain Therapeutics, in phase 2 trials for advanced solid tumours, cutaneous T-cell lymphoma and soft tissue sarcoma.","summary":"DT-7012 is a monoclonal antibody (depleting) from Domain Therapeutics. An anti-CCR8 antibody designed to remove highly immunosuppressive regulatory T cells from tumours through ADCC and ADCP. Its furthest stage is phase 2, for advanced solid tumours, cutaneous T-cell lymphoma and soft tissue sarcoma (undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma). ClinicalTrials.gov registers it in 3 studies linked below. Phase 1/2 DOMISOL (NCT06819735) recruiting; investigator trials in CTCL (NCT07213882, APHP) and soft tissue sarcoma (NCT07802652, Gustave Roussy, phase 2) not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Domain Therapeutics: kainovatx.com","url":"https://www.kainovatx.com/"},{"label":"Domain Therapeutics: kainovatx.com","url":"https://www.kainovatx.com/"},{"label":"ClinicalTrials.gov: trials of DT-7012","url":"https://clinicaltrials.gov/search?intr=DT-7012"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","cutaneous-t-cell-lymphoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["domain-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06819735","nct07213882","nct07802652"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DT-7012","modality":"Monoclonal antibody (depleting)","mechanism":"An anti-CCR8 antibody designed to remove highly immunosuppressive regulatory T cells from tumours through ADCC and ADCP.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dt-7012/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"company":[{"id":"domain-therapeutics","kind":"company","name":"Kainova Therapeutics","route":"/companies/domain-therapeutics/"}],"trial":[{"id":"nct07213882","kind":"trial","name":"A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)","route":"/trials/nct07213882/"},{"id":"nct07802652","kind":"trial","name":"Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma","route":"/trials/nct07802652/"},{"id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/"}]}}